Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 15, 2022

SELL
$8.77 - $18.29 $47,401 - $98,857
-5,405 Closed
0 $0
Q3 2021

Jun 21, 2023

BUY
$13.54 - $22.06 $73,183 - $119,234
5,405 New
5,405 $89,000
Q2 2021

Jun 21, 2023

BUY
$14.05 - $25.04 $75,940 - $135,341
5,405 New
5,405 $112,000
Q2 2021

Mar 30, 2023

BUY
$14.05 - $25.04 $62,944 - $112,179
4,480 Added 484.32%
5,405 $112,000
Q2 2021

Aug 16, 2021

BUY
$14.05 - $25.04 $75,926 - $135,316
5,404 Added 540400.0%
5,405 $112,000
Q1 2021

Jun 26, 2023

BUY
$16.57 - $28.65 $15,327 - $26,501
925 New
925 $17.3 Million
Q1 2021

Mar 30, 2023

SELL
$16.57 - $28.65 $57,033 - $98,613
-3,442 Reduced 78.82%
925 $17,000
Q1 2021

May 14, 2021

SELL
$16.57 - $28.65 $72,344 - $125,085
-4,366 Reduced 99.98%
1 $17,000
Q4 2020

Jun 22, 2023

BUY
$15.44 - $24.23 $67,426 - $105,812
4,367 New
4,367 $96,000
Q4 2020

Mar 30, 2023

BUY
$15.44 - $24.23 $339 - $533
22 Added 0.51%
4,367 $96,000
Q4 2020

Feb 16, 2021

BUY
$15.44 - $24.23 $339 - $533
22 Added 0.51%
4,367 $96,000
Q3 2020

Jun 26, 2023

BUY
$19.43 - $35.36 $84,423 - $153,639
4,345 New
4,345 $90,000
Q2 2020

Jun 26, 2023

BUY
$29.41 - $51.23 $127,786 - $222,594
4,345 New
4,345 $157,000
Q2 2020

Mar 30, 2023

BUY
$29.41 - $51.23 $61,908 - $107,839
2,105 Added 93.97%
4,345 $157,000
Q2 2020

Aug 14, 2020

BUY
$29.41 - $51.23 $61,908 - $107,839
2,105 Added 93.97%
4,345 $157,000
Q1 2020

Jul 12, 2023

BUY
$19.54 - $55.47 $49,846 - $141,503
2,551 New
2,551 $83,000
Q1 2020

Mar 30, 2023

BUY
$19.54 - $55.47 $43,769 - $124,252
2,240 New
2,240 $73,000
Q1 2020

May 15, 2020

BUY
$19.54 - $55.47 $43,769 - $124,252
2,240 New
2,240 $73,000

Others Institutions Holding APLT

About Applied Therapeutics Inc.


  • Ticker APLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,700
  • Market Cap $40.8M
  • Description
  • Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...
More about APLT
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.